Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
Authors:
- ComstockCOComstock
Open Access
- 1 March 2010
- journal article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 4, 215-225
Abstract
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Sterilization Sciences, Bausch and Lomb, Inc., Rochester, NY, USA; 4Global Preclinical Development, Bausch and Lomb, Inc., Rochester, NY, USA Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in preventing potentially irreversible ocular damage. However, the rise in ocular methicillin-resistant Staphylococcus aureus isolates and the patterns of fluoroquinolone resistance for patients with other ocular bacterial infections mandate the need for new agents targeted for ocular use. Besifloxacin, a novel broad-spectrum fluoroquinolone, is approved for the treatment of bacterial conjunctivitis. It has a uniquely balanced dual-targeting activity that inhibits both DNA gyrase and topoisomerase IV and is associated with a lower incidence of resistance development. Besifloxacin is not marketed in other formulations, ensuring that its exposure is limited to bacterial populations in and around the eye. This specifically precludes any bacterial exposure to besifloxacin resulting from systemic use, which further reduces the likelihood of emergence of bacterial resistance. In vitro, besifloxacin has demonstrated equivalent or superior activity compared with other commonly used topical antibiotics. In clinical trials, besifloxacin has consistently demonstrated efficacy and safety in the treatment of patients with bacterial conjunctivitis. Besifloxacin is considered safe and is well tolerated with no observed contraindications.Keywords: conjunctivitis, fluoroquinolones, besifloxacin, besivance, bacterial conjunctivitisKeywords
This publication has 23 references indexed in Scilit:
- Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic BacteriaAntimicrobial Agents and Chemotherapy, 2009
- New drugs: Golimumab, besifloxacin hydrochloride, and artemether/lumefantrineJournal of the American Pharmacists Association, 2009
- Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisCurrent Medical Research and Opinion, 2009
- Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2008
- Update on Bacterial Conjunctivitis in South FloridaOphthalmology, 2008
- Antimicrobial Efficacy of Gatifloxacin and Moxifloxacin with and without Benzalkonium Chloride Compared with Ciprofloxacin and Levofloxacin Against Methicillin- ResistantStaphylococcus aureusJournal of Chemotherapy, 2007
- Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolonesSurvey of Ophthalmology, 2004
- Immunomodulatory effects of quinolonesThe Lancet Infectious Diseases, 2003
- A systematic review of the associations between dose regimens and medication complianceClinical Therapeutics, 2001
- Emerging fluoroquinolone resistance in bacterial keratitisOphthalmology, 1999